BioNTech initiates the first Phase III clinical trial of B7-H3 ADC, expected to obtain results in January 2031
The U.S. ClinicalTrials.gov website shows that BioNTech has launched the first Phase III clinical trial of DB-1311/BNT324, expected to recruit 736 participants, with results anticipated in January 2031.
BNT324 is a B7-H3 ADC developed by DUALITYBIO (09606.HK), which was licensed to BioNTech in April 2023. The company holds the rights for the development, production, and commercialization of the drug outside of China
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments